Endovascular Therapy with Iliac Vein Stenting Benefits Patients with Post-Thrombotic Syndrome: NEJM
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2026-05-04 04:00 GMT | Update On 2026-05-04 04:00 GMT
Advertisement
USA: In the phase III C-TRACT trial, endovascular therapy using iliac vein stenting combined with enhanced antithrombotic therapy in patients with moderate-to-severe post-thrombotic syndrome and iliac vein obstruction resulted in significant improvement in disease severity and health-related quality of life at 6 months compared to usual care. However, this benefit was accompanied by an increased overall risk of bleeding, although major bleeding events remained uncommon, indicating a favorable but cautious risk–benefit profile for clinical practice.
Post-thrombotic syndrome (PTS) is a frequent and often debilitating long-term complication of deep-vein thrombosis, characterized by chronic limb pain, swelling, and functional limitation that significantly impair daily activities and overall well-being. Persistent venous obstruction, particularly in the iliac veins, plays a key role in the pathophysiology of PTS. Endovascular approaches, including stent placement to restore venous outflow, have been proposed as a strategy to alleviate these symptoms, but robust randomized evidence has been limited until now.
To address this gap, Suresh Vedantham and colleagues conducted the phase III C-TRACT trial, published in the New England Journal of Medicine. The study included 225 patients with imaging-confirmed iliac vein obstruction and moderate-to-severe PTS, randomly assigned to endovascular therapy (iliac vein stenting plus intensified antithrombotic therapy) with standard care or standard care alone. The primary outcome was PTS severity at 6 months, measured using the Venous Clinical Severity Score (VCSS; 0–30 scale), with blinded outcome assessment.
Key Findings:
- At 6 months, endovascular therapy significantly reduced post-thrombotic syndrome (PTS) severity compared to standard care alone.
- Mean Venous Clinical Severity Score (VCSS) was 8.1 in the intervention group vs 10.0 in the control group.
- Adjusted mean difference in VCSS was −2.0 points, indicating a statistically significant improvement.
- Findings suggest that iliac vein stenting and relief of venous obstruction lead to clinically meaningful symptom reduction.
- Patients receiving endovascular therapy showed significantly better venous disease–specific quality of life.
- VEINES-QOL scores improved by an adjusted difference of 14.5 points in the intervention group
- Overall physical health status also improved, with SF-36 physical component scores increasing by 6.1 points.
- Results indicate a positive impact on functional status and daily living.
- Bleeding events were more frequent in the endovascular therapy group over 6 months.
- Bleeding occurred in 11.6% of patients in the intervention group vs 3.6% in the standard care group.
- The increase in bleeding risk was statistically significant.
- Major bleeding events were rare, suggesting risks may be manageable with careful patient selection and monitoring.
Overall, the C-TRACT trial provides important evidence supporting the use of endovascular therapy in selected patients with moderate-to-severe PTS and iliac vein obstruction. The findings highlight a clear improvement in symptom burden and quality of life, balanced against a higher, yet generally manageable, risk of bleeding.
Reference:
DOI: 10.1056/NEJMoa2519001
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.